{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:26:38Z","timestamp":1768364798006,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:p>Multiple sclerosis (MS) is a disease of the central nervous system in which the immune system attacks the myelin sheath that covers nerve fibers. It is an immune-mediated chronic inflammatory disease. Teriflunomide is a once-daily oral disease modifying therapy that was approved by the FDA for relapsing-remitting MS. This study aims to assess the effectiveness and tolerability of teriflunomide in MS patients in Saudi Arabia. A multicenter retrospective study conducted in 2 tertiary medical centers with specialized MS clinics in Saudi Arabia. All patients who used teriflunomide from March 2016 to September 2020 were included. A total of 38 people with MS (pwMS) were included which were predominantly female (60.5%) with a mean age of 37.1 years. In our study, 23.7% of pwMS on teriflunomide experienced at least 1 clinical relapse. Following the initiation of teriflunomide, 26.3% of the patients developed at least 1 new lesion on magnetic resonance imaging of the brain. No evidence of disease activity 3 was achieved in 63.2% of pwMS. Teriflunomide was discontinued in 14 (36.8%) patients. The most common reason for discontinuation was adverse effects (AEs) as reported by 8 (57.1%) patients. Overall, 18 (47.4%) of patients have experienced treatment AEs. The most reported type of AEs was hair thinning or loss which was reported by 15.8% of patients. Teriflunomide was modestly effective in controlling disease activity in pwMS in Saudi Arabia with the majority achieving no evidence of disease activity 3, although the mean expanded disability status scale increased slightly. However, the discontinuation rate was high most commonly due to AEs. Overall, the safety profile was consistent with real-world experience. Larger local studies are needed to confirm this finding.<\/jats:p>","DOI":"10.1097\/md.0000000000045156","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:02:59Z","timestamp":1760331779000},"page":"e45156","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Teriflunomide treatment for relapsing-remitting multiple sclerosis: An experience from Saudi Arabia"],"prefix":"10.1097","volume":"104","author":[{"given":"Morad","family":"Aljinaid","sequence":"first","affiliation":[{"name":"Neuroscience Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-6701","authenticated-orcid":false,"given":"Osama","family":"Khojah","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"},{"name":"Department of Neurology, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layan","family":"Arshad","sequence":"additional","affiliation":[{"name":"Neuroscience Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Algahtani","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"},{"name":"Department of Neurology, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyad","family":"Alghweinem","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"Department of Neurology, Ministry of The National Guard-Health Affairs, Riyadh, Saudi Arabia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sultan","family":"Alshehri","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"Department of Neurology, Ministry of The National Guard-Health Affairs, Riyadh, Saudi Arabia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Abulaban","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"Department of Neurology, Ministry of The National Guard-Health Affairs, Riyadh, Saudi Arabia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"Department of Neurology, Ministry of The National Guard-Health Affairs, Riyadh, Saudi Arabia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0892-8669","authenticated-orcid":false,"given":"Seraj","family":"Makkawi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"},{"name":"Department of Neurology, Ministry of the National Guard-Health Affairs, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260113","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology.","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurol"},{"key":"R2-20260113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"R3-20260113","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability.","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"R4-20260113","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/pharmaceutics16010120","article-title":"Personalized use of disease-modifying therapies in multiple sclerosis.","volume":"16","author":"Lee","year":"2024","journal-title":"Pharmaceutics"},{"key":"R5-20260113","first-page":"8","article-title":"Teriflunomide for multiple sclerosis. Cochrane multiple sclerosis and rare diseases of the CNS Group, ed.","volume":"2016","author":"He","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20260113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0404.2010.01444.x","article-title":"Pathophysiology of multiple sclerosis and the place of teriflunomide: MS pathophysiology and the place of teriflunomide.","volume":"124","author":"Gold","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.msard.2018.09.017","article-title":"Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: results from the global Phase 4 Teri-PRO study in routine clinical practice.","volume":"26","author":"Coyle","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"R8-20260113","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"R9-20260113","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.","volume":"66","author":"O\u2019Connor","year":"2006","journal-title":"Neurology"},{"key":"R10-20260113","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis.","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"R11-20260113","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1756285617722500","article-title":"Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.","volume":"10","author":"Miller","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"R12-20260113","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1007\/s00415-022-11118-7","article-title":"Real-world outcomes of teriflunomide in relapsing\u2013remitting multiple sclerosis: a prospective cohort study.","volume":"269","author":"Zhang","year":"2022","journal-title":"J Neurol"},{"key":"R13-20260113","doi-asserted-by":"crossref","first-page":"175628641983507","DOI":"10.1177\/1756286419835077","article-title":"Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study.","volume":"12","author":"Kallmann","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"R14-20260113","doi-asserted-by":"crossref","first-page":"e0250820","DOI":"10.1371\/journal.pone.0250820","article-title":"Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. Ramagopalan SV, ed.","volume":"16","author":"Papp","year":"2021","journal-title":"PLoS One"},{"key":"R15-20260113","doi-asserted-by":"crossref","first-page":"204","DOI":"10.17712\/nsj.2018.3.20180003","article-title":"Tolerability and discontinuation rates in teriflunomide-treated patients: a real-world clinical experience.","volume":"23","author":"Alnajashi","year":"2018","journal-title":"Neurosciences (Riyadh)"},{"key":"R16-20260113","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12883-021-02317-2","article-title":"Differential disease phenotypes and progression in relapsing\u2013remitting multiple sclerosis: comparative analyses of single Canadian and Saudi Arabian clinics.","volume":"21","author":"Alluqmani","year":"2021","journal-title":"BMC Neurol"},{"key":"R17-20260113","first-page":"205521732210771","article-title":"Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: an expert consensus narrative review.","volume":"8","author":"Alroughani","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"R18-20260113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/ctn6040027","article-title":"Saudi consensus recommendations on the management of multiple sclerosis: disease-modifying therapies and management of relapses.","volume":"6","author":"Al Malik","year":"2022","journal-title":"Clin Transl Neurosci"},{"key":"R20-20260113","doi-asserted-by":"crossref","first-page":"10042","DOI":"10.3390\/ijerph181910042","article-title":"A Saudi Arabian public health perspective of tuberculosis.","volume":"18","author":"Saati","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R21-20260113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00430-016-0482-x","article-title":"Effect of teriflunomide on QuantiFERON-TB gold results.","volume":"206","author":"Bua","year":"2017","journal-title":"Med Microbiol Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:03:09Z","timestamp":1768334589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":20,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045156","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"2025-07-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}